Open Label Excerpt: We still have to rely heavil
Post# of 148282
(Total Views: 642)
Posted On: 12/25/2020 12:47:23 PM
Open Label Excerpt: We still have to rely heavily on post-marketing safety surveillance systems to alert us to type B (unpredictable) adverse reactions because open-label extension studies are unlikely to provide useful information about these types of often serious and relatively rare adverse reactions
Read More: https://investorshangout.com/post/newpost/605...z6hevfovzG
LL has been in type B study for years. We are ahead of the game. GLTA.
Read More: https://investorshangout.com/post/newpost/605...z6hevfovzG
LL has been in type B study for years. We are ahead of the game. GLTA.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼